Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I always have this question. If they have 3rd submission now, or by the end of the month, which PPS could it reach? Like short time 0.08?
If it is clear that it will drop to 0.007 first, we should just watch world cup and not sitting here. But they said the 3rd submission would be by the end of month. So what will happen first? R/S or 3rd?
Yes, the R/S will not happen today. But the vote will be yes. The real R/S will be from end of July to September, I guess.
Great! Do like James Bond. But to me 0.0007 or 0.0008 is the same.
Good idea! Could you tell where to check LTCO's selling?
I feel that the MMs are watching us all the time and because they know what we are thinging, they will use the best to get money from us.
Sure, sweetgirl, I see clearly what you said.
I think everyone is just waiting this which will induce a sharp (short) jump. But according to Smitter, either this will happen late or the jump will be small and it it goes to 0.01 before the real RS, which may happen in late July.
The big question is that if this will happen that late? According to the PR, it is at 2nd of quater.
Kei, our new smart girl. I agree with you on GETA. But still one thing not clear, when would they have the SPA? By the end of the month? You even guess may around 15th Jun. According to Smitter, this may happen in July.
What data?
I am long on NEPH anyway.
Could it be a good news?
Liberty Analytics Co. Initiates Independent Research Coverage on Genta Incorporated
CALGARY, Alberta, May 26, 2010 (GlobeNewswire via COMTEX) -- Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on Genta Incorporated /quotes/comstock/11k!geta (GETA 0.05, +0.00, +4.21%) . Liberty Analytics is currently offering a complimentary trial subscription. To view our research, go to: www.libertyanalyticsco.com
About LAC:
Liberty Analytics Co. is a leading provider of independent investment research in North America. Our services include research analysis on the large, small- and micro-cap markets, real-time news and financial data, market commentary and the LAC newsletter. Liberty Analytics' staff of large and small-cap investment professionals is dedicated to providing the market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.libertyanalyticsco.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.libertyanalyticsco.com/signup.php
About Genta Incorporated /quotes/comstock/11k!geta (GETA 0.05, +0.00, +4.21%) :
Genta Incorporated /quotes/comstock/11k!geta (GETA 0.05, +0.00, +4.21%) is a biopharmaceutical company engaged in pharmaceutical (drug) research and development. The Company focuses on the identification, development and commercialization of drugs for the treatment of cancer and related diseases.
LAC Disclosure:
Libertyanalyticsco.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Liberty Analytics has not been compensated by any of the above-mentioned companies. Please read our report and visit our Web site, www.libertyanalyticsco.com, for complete risks and disclosures.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Liberty Analytics Company
From the May 21, 2010 S-1 report to the SEC - If we do not receive
FDA approval for our OLpur H 2 H hemodiafiltration module and OLpur
MD220 hemodiafilter our operations will be significantly and adversely
harmed.
We have not received approval from the FDA for our OLpur H 2 H
hemodiafiltration module and OLpur MD220 hemodiafilter. We received
conditional approval for our IDE application from the FDA to begin
human clinical trials of our OLpur H 2 H hemodiafiltration module and
OLpur MD220 hemodiafilter. We were granted this approval on the
condition that, by March 5, 2007, we submit a response to two
informational questions from the FDA. We responded to these questions.
We obtained approval from Western IRB, Inc., which enabled us to
proceed with our clinical trial. We completed the patient treatment
phase of our clinical trial during the second quarter of 2008. We
submitted our data to the FDA with our 510(k) application on these
products in November 2008. Following its review of the application,
the FDA requested additional information from us. We replied to the
FDA inquiries on March 13, 2009. The FDA has not provided us with any
additional requests for information or rendered a decision on our
application. We have made additional inquiries to the FDA about the
status of our application and, on March 10, 2010, were informed that
our application is still under their review process. We can give no
assurance when or if our OLpur H 2 H hemodiafiltration module and
OLpur MD220 hemodiafilter will be approved by the FDA. If we fail to
receive FDA approval or if the approval is delayed into the third
quarter of 2010, our operations would be significantly and adversely
harmed.
Smitter, you said there might be a ASCO pump coming. Are you going to have some entry points for this? Let us say 0.03? I think it might not go to 0.01 before the ASCO according to your ideas.
What kind of news could it be? The recent spike is 0.065 of PPS and the biggest on eis 0.12. Do you think it may reach that again?
My god! They are showing them how to short themselves! So most of the stockholders are just idiots to them.
Thanks! Smitter!
We are coming near to the D-day, right?
Hope something would happen soon. The window is getting closed.
Hi Guys,
Should we be more active on this board?
From following Form 10-Q for NEPHROS INC, I can see that they may dilute soon and that is why the PPS is dropping. And we all know [color=red]the waiting is too long and seems endless.
Well guys, at the same time, there are good news from time to time. It is quite a difficult stock.
Immediate Need for Capital
We have incurred significant losses in our operations in each quarter since inception. In addition, we have not generated positive cash flow from operations for the year ended December 31, 2008 or 2009 or for the three months ended March 31, 2010. Our recurring losses and difficulty in generating sufficient cash flow to meet our obligations and sustain our operations raise substantial doubt about our ability to continue as a going concern. We need to raise operating funds through either the licensing or sale of our technologies or public or private offerings of our securities. While we are investigating strategic funding opportunities, we might not be able to raise funds on a timely basis or on acceptable terms or at all. If we fail to raise capital, our funds will be depleted in the third quarter of 2010, and we might not be able to continue our operations.
It is amazing! Why not falling like a rock rifht now? Maybe later?
At least to me this news is so terrible! I hope it is the worst time before the good news.
Smitter,
Where could you see the price and volume of pre-market?
What is happenning now?
Huge volume these days at 0.02, 0.03 and 0.04 at Pre-market.
It may go there finally as you guess, if not worse.
I am wondering when are you going to put one of your toes into it. I may start from 0.04.
I see. Thanks!
I will prefer to jump into the Geneve lake instead.
Smitter said it clearly the time is after R/S. But before that, there seems some blood on the knife and some people want to lick. By the way I am in Eu and I do not know the fun at the Brooklyn Bridge.
You know, it is so boring to wait and wait. So just speak something. At least there is a little hope. Do you expect the fast track when it went to 0.04? And then if you came out at 0.17, you can just wait for next months.
Anyway time is a big issue and if you have some nice ideas, just share with us. In most developing bio-stocks, in most of the time it is boring but only few people are lucky like those in DNDN.
I do not mind if you are sure of other candidates. I would say, for example, NEPH.
Rey will give a presentation about all the collaborations. So it is possible there is something in it.
Guys, are you all sleeping?
There should be something in 6th May meeting. Remember thay will release a huge news within two months.
The reason for today’s drop___a message from discussion board at Google
According to SEC filing - section (c) under conversion of outstanding
notes; each holder agreed not to sell or transfer any common shares
until 11:59ET April 26th
Thus today, the 27th , was the first opportunity for note holders to
sell if desired. One should remember, note holders only converted to
common shares they are not required to sell. Many will hold and reap
the benefits of this coming year.
“Conversion drop days” such as today generally works out to 2/3
conversion sellers and 1/3 panic sell. Considering it only dropped a
0.017 I am very impressed and even more optimistic of this stock.
If anyone is wondering today is a great day to buy or average down.
The damage has been done.
More dates to know:
On June 15, 2010 will be the annual share holders meeting. Investors
holding as of April 26th will have the opportunity to vote to effect
a reverse stock split. If approved the Board of directors would have
the authority to effect a RS anytime before the 2011 meeting. Thus
any reverse split does not have to happen ASAP; the board has the
flexibility to set the date and ratio according to market conditions
in the best interest of the shareholders.
Reverse splits are usually considered an ugly thing because companies
doing them are generally in trouble, the stock has tumbled and they
have received notice of non compliance and will be booted off the
exchange. This is not the case for GETA. GETA wants this reverse
split for the garden variety cosmetic reasons. Improve perception,
appeal to broader range of investors and keep investor transaction
costs down.
More importantly this Reverse split will keep shares numbers within
the authorized limits come note conversion time. Trust me you would
much rather see note holders paid out with stock instead of cash.
Here’s the part I don’t like, GETA also states that a reverse split
would leave required shares available for future issuance. Dilution is
such an ugly word but the company would not do this needlessly and as
of March they have 25 mil for operating costs and a potential FDA
approval in less than a year. So it may never be necessary.
Once again it is a VOTE
Cut and paste to this link below. This is one of my favourite
articles regarding reverse splits. Read it all the way through
because when you get to the end about the 25% companies that sky
rocket after a reverse split I believe GETA might apply because the
reasons for the RS is cosmetic, for authorized share limits and 2010
prospects have definitely improved.
http://moneycentral.msn.com/content/P32972.asp
About Fast track designation (most of this purloined from wikipedia
but it had the best explanation.) Tesetaxel has left an impression on
the FDA as it must show all of the below to even be considered
• Showing superior effectiveness
• Avoiding serious side effects of an available treatment
• Improving the diagnosis of a serious disease where early diagnosis
results in an improved outcome
A drug that receives Fast Track designation is eligible for some or
all of the following:
• More frequent meetings with FDA to discuss the drug’s development
plan and ensure collection of appropriate data needed to support drug
approval
• More frequent written correspondence from FDA about such things as
the design of the proposed clinical trials
• Eligibility for FDA Accelerated Approval,
In addition, most drugs that are eligible for Fast Track designation
are likely to be considered appropriate to receive a Priority Review.
Fast Track designation must be requested by the drug company. The
request can be initiated at any time during the drug development
process. FDA will review the request and make a decision within sixty
days based on whether the drug fills an unmet medical need in a
serious disease.
In short the reson why almost every fast track drug wins FDA approval
is:
1) It is a very promising drug to begin with. Safety being #1
2) because they have the luxury of more communication with the FDA.
Insuring the New Drug Application has all of the t’s are crossed and
I’s are dotted before the approval date.
GETA may apply for priority review when ever it feels it has met the
FDA requirements.
Don’t get too freaked about about today’s price. Today was written in
the SEC filings. The only thing anyone should be is bullish about
this stock an FDA approval for a cancer drug possibly within the year
is a winner.
Disclosure: I am in 700k, It is my intention to play this one right up
until approva.l If you want some fun read back all the discussions
from the past three weeks ..the mania and depression. This stocks’
price causes light switch bi polar effects on investors please don’t
get sucked in The facts and future have not changed.
GLTA
I guess that it is the only card in hand: secure a SPA.
At the moment, the down trend is quite strong.
Genta plans to submit its proposed Phase 3 trial to FDA in the 2nd-quarter in order to secure a Special Protocol Assessment (SPA). The Company looks forward to meeting with the FDA to discuss the trial design.
It is dropping fast, well not finish yet.
You have a good guess about the time.
One thing I am not clear:
Genta also finished the study of Roche’s Xeloda (capecitabine. Is that something new and maybe good?
FDA Grants Fast-Track Status to Genta’s, Allon’s Drugs
The FDA has granted fast-track status to Genta’s gastric cancer treatment tesetaxel and Allon Therapeutics’ neuroprotective drug davunetide. Genta expects to submit its plan for a randomized, double-blind, placebo-controlled Phase III trial to the FDA in the second quarter, the company said last week. Genta has completed a dose-ranging and pharmacokinetic study of tesetaxel plus Roche’s Xeloda (capecitabine).
One thing interesting. This time the volume is rather low compared to the big drop before the the big news one week ago. It seems people are just waiting. And at the same time, the notes are released slowly and continuously.
Where are those German guys?
It seems that without big news, it will techniquely point to 0.09 and then 0.06 and then 0.03 instead of 0.25.
But I feel they have that news at hand. Just wondering when they will release it. Before or after 15th Jun?
Do you guys have any ideas?
Let us watching closely. It will test 0.09 support soon.
Thanks!
So it means nothing much we can expected from this meeting.
The PPS is going down slowly, maybe continue this week. I hope at least there will be a technique rebound at 0.09.
Otherwise we have to wait a good news which usually takes time.
Hi, guys,
Today is the last day of the AACR Annual Meeting. Do you hear any news from Genta?
Thanks!
So what is the final possible number of billions?
2.7 is not enough? Then 6 or more?
I agree with you for the short term movement. The only news for tnext pump will be with th eprogress with FDA.
Float will be 2.7 billion. R/S: Maybe 1:20?
I guess the bottom before R/S would be 0.02-0.03
Hi, but the meeting is 15th Jun. Right? What is the event in 30th April?